AU2008338063B2 - RhoC-based immunotherapy - Google Patents

RhoC-based immunotherapy Download PDF

Info

Publication number
AU2008338063B2
AU2008338063B2 AU2008338063A AU2008338063A AU2008338063B2 AU 2008338063 B2 AU2008338063 B2 AU 2008338063B2 AU 2008338063 A AU2008338063 A AU 2008338063A AU 2008338063 A AU2008338063 A AU 2008338063A AU 2008338063 B2 AU2008338063 B2 AU 2008338063B2
Authority
AU
Australia
Prior art keywords
seq
rhoc
hla
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008338063A
Other languages
English (en)
Other versions
AU2008338063A1 (en
Inventor
Mads Hald Andersen
Per Thor Straten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhovac ApS
Original Assignee
Rhovac ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhovac ApS filed Critical Rhovac ApS
Publication of AU2008338063A1 publication Critical patent/AU2008338063A1/en
Application granted granted Critical
Publication of AU2008338063B2 publication Critical patent/AU2008338063B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008338063A 2007-12-19 2008-12-18 RhoC-based immunotherapy Ceased AU2008338063B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701844 2007-12-19
DKPA200701844 2007-12-19
PCT/DK2008/050324 WO2009076966A2 (en) 2007-12-19 2008-12-18 Rhoc-based immunotherapy

Publications (2)

Publication Number Publication Date
AU2008338063A1 AU2008338063A1 (en) 2009-06-25
AU2008338063B2 true AU2008338063B2 (en) 2013-03-14

Family

ID=59270757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008338063A Ceased AU2008338063B2 (en) 2007-12-19 2008-12-18 RhoC-based immunotherapy

Country Status (9)

Country Link
US (3) US9163077B2 (enExample)
EP (1) EP2234635B1 (enExample)
JP (3) JP2011506497A (enExample)
AU (1) AU2008338063B2 (enExample)
CA (1) CA2710061C (enExample)
DK (1) DK2234635T3 (enExample)
ES (1) ES2623447T3 (enExample)
PL (1) PL2234635T3 (enExample)
WO (1) WO2009076966A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710061C (en) * 2007-12-19 2022-07-12 Rhovac Aps Rhoc-based immunotherapy
US10019634B2 (en) * 2010-06-04 2018-07-10 Masoud Vaziri Method and apparatus for an eye tracking wearable computer
US20190382454A1 (en) * 2015-03-05 2019-12-19 Amrita Therapeutics Limited A modified peptide as an anticancer agent
WO2019094326A1 (en) 2017-11-08 2019-05-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using rhoa dominant negative forms
KR101947452B1 (ko) * 2018-04-26 2019-02-13 주식회사 에스와이테크 하이브리드 acp 시스템 및 그 제조방법
KR200488051Y1 (ko) * 2018-05-28 2018-12-07 주식회사 에스와이테크 완충 z-바
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033870A2 (en) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human regulatory proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US6814968B1 (en) * 1998-06-04 2004-11-09 Vanderbilt University Inhibition of viral infection and spread with viral and RhoA-derived peptides
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2088801A (en) 1999-12-10 2001-06-18 Dana-Farber Cancer Institute, Inc. Metastasis genes and uses thereof
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7194802B2 (en) * 2002-03-26 2007-03-27 Seagate Technology Llc Tool for certifying a head-gimbal assembly
DE10217035A1 (de) * 2002-04-11 2004-01-22 Universitätsklinikum Charité Medizinische Fakultät der Humboldt-Universität Akademische Verwaltung - Forschung Rekrutierungsmodule von RhoA und RhoC
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
US7960100B1 (en) * 2004-04-30 2011-06-14 Celera Corporation Colon cancer targets and uses thereof
US7763418B2 (en) * 2005-07-05 2010-07-27 Cytoskeleton, Inc. Detection of Rho proteins
CA2710061C (en) * 2007-12-19 2022-07-12 Rhovac Aps Rhoc-based immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033870A2 (en) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human regulatory proteins

Also Published As

Publication number Publication date
DK2234635T3 (en) 2017-05-01
JP2014139185A (ja) 2014-07-31
WO2009076966A2 (en) 2009-06-25
US20160008448A1 (en) 2016-01-14
CA2710061A1 (en) 2009-06-25
WO2009076966A3 (en) 2009-08-20
ES2623447T3 (es) 2017-07-11
JP6084671B2 (ja) 2017-02-22
US9163077B2 (en) 2015-10-20
EP2234635B1 (en) 2017-01-25
US20110002954A1 (en) 2011-01-06
AU2008338063A1 (en) 2009-06-25
US20190247480A1 (en) 2019-08-15
CA2710061C (en) 2022-07-12
EP2234635A2 (en) 2010-10-06
JP2016014043A (ja) 2016-01-28
JP5813801B2 (ja) 2015-11-17
JP2011506497A (ja) 2011-03-03
PL2234635T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
US20190247480A1 (en) RhoC-Based Immunotherapy
AU2004290866B2 (en) Proteins belonging to the BcL-2 family and fragments thereof, and their use in cancer patients
EP3291830B1 (en) Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US20080107668A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20060045881A1 (en) Anti-cancer vaccines
WO2009036246A2 (en) Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
CA2772551A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2005035714A2 (en) Vaccines for cancer, autoimmune disease and infections
US20060045883A1 (en) Anti-cancer vaccines
US9475841B2 (en) Melanoma antigen peptide and uses thereof
US20060045884A1 (en) Vaccines for autoimmune and infectious disease
US9573975B2 (en) Melanoma antigen peptide and uses thereof
HK1101131B (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired